GSK plc

GSK plc P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of GSK plc (GSK.L) as of Oct 19, 2026 is 14.67. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 24.45 — a change of -40.02% (lower).

P/FCF

14.67

YoY

-40.02%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of GSK plc is 2025 14.67 . P/FCF (Price-to-Free-Cash-Flow Ratio) of GSK plc was 2024 24.45 . It decreases by -40.02% lower compared to the previous year.

The GSK plc P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
13.19 GBP
Jan 1, 2019
14.91 GBP
Jan 1, 2020
14.08 GBP
Jan 1, 2021
17.40 GBP
Jan 1, 2022
16.98 GBP
Jan 1, 2023
19.75 GBP
Jan 1, 2024
24.45 GBP
Jan 1, 2025
14.67 GBP
The GSK plc P/FCF history
YEARP/FCFYoY
14.67-40.02%
24.45+23.85%
19.75+16.30%
16.98-2.41%
17.40+23.52%
14.08-5.56%
14.91+13.11%
13.19-28.82%
18.52-12.11%
21.07-83.88%
130.77+412.72%
25.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GSK plc Stock analysis

What does GSK plc do? GSK plc, listed on the London Stock Exchange under the ticker GSK.L, is a pharmaceutical company headquartered in Brentford, United Kingdom. The company, which has been publicly traded since May 22, 1972, operates within the healthcare sector, specifically in the pharmaceuticals industry. GSK employs 94,066 full-time staff, focusing on the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. The company's operations are structured around two primary segments: Pharmaceuticals and Vaccines. In the Pharmaceuticals segment, GSK develops and markets medicines for a variety of conditions, including respiratory diseases, HIV and infectious diseases, immuno-inflammation, oncology, and rare diseases. The Vaccines segment provides immunization solutions for all age groups, from infants to the elderly, including pediatric, adolescent, adult, and travel vaccines. GSK's portfolio includes prescription medicines and vaccines, with a particular emphasis on respiratory and HIV-related treatments. The company's business strategy encompasses both innovative therapeutic areas and established product lines, supporting its global presence in healthcare. GSK's official website is www.gsk.com, offering further information about its products and initiatives. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of GSK plc is 14.67 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of GSK plc changed from 24.45 to 14.67, representing a -40.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) GSK plc since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s GSK plc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — GSK plc

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — GSK plc